Achenbach, T. M., McConaughy, S. H., and Howell, C. T. (1987). Child/adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychol Bull, 101, 213–232.Google Scholar

Allen, A. M., Jung, A. M., Alexander, A. C., et al. (2020). Cannabis use and stressful life events during the perinatal period: Cross-sectional results from Pregnancy Risk Assessment Monitoring System (PRAMS) data, 2016. Addiction, 115, 1707–1716.Google Scholar

Alshaarawy, O., and Anthony, J. C. (2019). Are cannabis users less likely to gain weight? Results from a national 3-year prospective study. Int J Epidemiol, 48, 1695–1700.CrossRefGoogle ScholarPubMed

Antonelli, T., Tomasini, M. C., Tattoli, M., et al. (2005). Prenatal exposure to the CB1 receptor agonist WIN 55,212-2 causes learning disruption associated with impaired cortical NMDA receptor function and emotional reactivity changes in rat offspring. Cereb Cortex, 15, 2013–2020.Google Scholar

Bada, H. S., Bann, C. M., Bauer, C. R., et al. (2011). Preadolescent behavior problems after prenatal cocaine exposure: Relationship between teacher and caretaker ratings (Maternal Lifestyle Study). Neurotoxicol Teratol, 33, 78–87.Google Scholar

Baer, R. J., Chambers, C. D., Ryckman, K. K., et al. (2019). Risk of preterm and early term birth by maternal drug use. J Perinatol, 39, 286–294.Google Scholar

Bara, A., Manduca, A., Bernabeu, A., et al. (2018). Sex-dependent effects of in utero cannabinoid exposure on cortical function. eLife, 7, e36234.Google Scholar

Basavarajappa, B. S., Nixon, R. A., and Arancio, O. (2009). Endocannabinoid system: Emerging role from neurodevelopment to neurodegeneration. Mini Rev Med Chem, 9, 448–462.Google Scholar

Bayrampour, H., Zahradnik, M., Lisonkova, S., et al. (2019). Women’s perspectives about cannabis use during pregnancy and the postpartum period: An integrative review. Prev Med, 119, 17–23.Google Scholar

Belbasis, L., Savvidou, M. D., Kanu, C., et al. (2016). Birth weight in relation to health and disease in later life: An umbrella review of systematic reviews and meta-analyses. BMC Med, 14, 147.Google Scholar

Berrendero, F., García-Gil, L., Hernández, M. L., et al. (1998). Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development, 125, 3179–3188.CrossRefGoogle ScholarPubMed

Bolhuis, K., Kushner, S. A., Yalniz, S., et al. (2018). Maternal and paternal cannabis use during pregnancy and the risk of psychotic-like experiences in the offspring. Schizophr Res, 202, 322–327.Google Scholar

Brancato, A., Castelli, V., Lavanco, G., et al. (2020). In utero Δ9-tetrahydrocannabinol exposure confers vulnerability towards cognitive impairments and alcohol drinking in the adolescent offspring: Is there a role for neuropeptide Y? J Psychopharmacol (Oxf), 34, 663–679.Google Scholar

Breit, K. R., Rodriguez, C. G., Lei, A., et al. (2020). Combined vapor exposure to THC and alcohol in pregnant rats: Maternal outcomes and pharmacokinetic effects. Neurotoxicol Teratol, 82, 106930.Google Scholar

Brents, L. K. (2017). Correlates and consequences of prenatal cannabis exposure (PCE): Identifying and characterizing vulnerable maternal populations and determining outcomes for exposed offspring. In: Preedy, V. R. (ed.), Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment (pp. 160–170). London: Elsevier Inc.Google Scholar

Campolongo, P., Trezza, V., Cassano, T., et al. (2007). Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats. Addict Biol, 12, 485–495.Google Scholar

Carmody, D. P., Bennett, D. S., and Lewis, M. (2011). The effects of prenatal cocaine exposure and gender on inhibitory control and attention. Neurotoxicol Teratol, 33, 61–68.Google Scholar

Cecil, C. A. M., Walton, E., Smith, R. G., et al. (2016). DNA methylation and substance-use risk: A prospective, genome-wide study spanning gestation to adolescence. Transl Psychiatry, 6, e976.Google Scholar

Chabarria, K. C., Racusin, D. A., Antony, K. M., et al. (2016). Marijuana use and its effects in pregnancy. Am J Obstet Gynecol, 215, 506.e1–506.e7.CrossRefGoogle ScholarPubMed

Chen, D. J., Gao, M., Gao, F. F., et al. (2017). Brain cannabinoid receptor 2: Expression, function and modulation. Acta Pharmacol Sin, 38, 312–316.CrossRefGoogle ScholarPubMed

Compton, W. M., Han, B., Jones, C. M., et al. (2016). Marijuana use and use disorders in adults in the USA, 2002–14: Analysis of annual cross-sectional surveys. Lancet Psychiatry, 3, 954–964.Google Scholar

Conner, S. N., Bedell, V., Lipsey, K., et al. (2016). Maternal marijuana use and adverse neonatal outcomes: A systematic review and meta-analysis. Obstet Gynecol, 128, 713–723.Google Scholar

Cornelius, M. D., Taylor, P. M., Geva, D., et al. (1995). Prenatal tobacco and marijuana use among adolescents: Effects on offspring gestational age, growth, and morphology. Pediatrics, 95, 738–743.Google Scholar

Corsi, D. J., Walsh, L., Weiss, D., et al. (2019). Association between self-reported prenatal cannabis use and maternal, perinatal, and neonatal outcomes. JAMA, 322, 145–152.Google Scholar

Crume, T. L., Juhl, A. L., Brooks-Russell, A., et al. (2018). Cannabis use during the perinatal period in a state with legalized recreational and medical marijuana: The association between maternal characteristics, breastfeeding patterns, and neonatal outcomes. J Pediatr, 197, 90–96.Google Scholar

Day, N. L., Leech, S. L., and Goldschmidt, L. (2011). The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. Neurotoxicol Teratol, 33, 129–136.CrossRefGoogle ScholarPubMed

Day, N. L., and Richardson, G. A. (1991). Prenatal marijuana use: Epidemiology, methodologic issues, and infant outcome. Clin Perinatol, 18, 77–91.CrossRefGoogle ScholarPubMed

Day, N. L., Richardson, G. A., Goldschmidt, L., et al. (1994). Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol, 16, 169–175.CrossRefGoogle ScholarPubMed

Day, N. L., Sambamoorthi, U., Taylor, P., et al. (1991). Prenatal marijuana use and neonatal outcome. Neurotoxicol Teratol, 13, 329–334.Google Scholar

Dinieri, J. A., Wang, X., Szutorisz, H., et al. (2011). Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry, 70, 763–769.Google Scholar

El Marroun, H., Bolhuis, K., Franken, I. H. A., et al. (2019). Preconception and prenatal cannabis use and the risk of behavioural and emotional problems in the offspring; a multi-informant prospective longitudinal study. Int J Epidemiol, 48, 287–296.Google Scholar

El Marroun, H., Tiemeier, H., Jaddoe, V. W. V., et al. (2008). Demographic, emotional and social determinants of cannabis use in early pregnancy: The Generation R study. Drug Alcohol Depend, 98, 218–226.Google Scholar

El Marroun, H., Tiemeier, H., Steegers, E. A., et al. (2009). Intrauterine cannabis exposure affects fetal growth trajectories: The Generation R study. J Am Acad Child Adolesc Psychiatry, 48, 1173–1181.Google Scholar

ElSohly, M. A., Mehmedic, Z., Foster, S., et al. (2016). Changes in cannabis potency over the last 2 decades (1995–2014): Analysis of current data in the United States. Biol Psychiatry, 79, 613–619.Google Scholar

Fan, R. G., Portuguez, M. W., and Nunes, M. L. (2013). Cognition, behavior and social competence of preterm low birth weight children at school age. Clinics, 68, 915–921.Google Scholar

Fine, J. D., Moreau, A. L., Karcher, N. R., et al. (2019). Association of prenatal cannabis exposure with psychosis proneness among children in the Adolescent Brain Cognitive Development (ABCD) study. JAMA Psychiatry, 76, 762.Google Scholar

Frau, R., Miczan, V., Traccis, F., et al. (2019). Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone. Nat Neurosci, 22, 1975–1985.Google Scholar

Fried, P. A. (1995). The Ottawa Prenatal Prospective Study (OPPS): Methodological issues and findings – it’s easy to throw the baby out with the bath water. Life Sci, 56, 2159–2168.Google Scholar

Fried, P. A., and O’Connell, C. M. (1987). A comparison of the effects of prenatal exposure to tobacco, alcohol, cannabis and caffeine on birth size and subsequent growth. Neurotoxicol Teratol, 9, 79–85.Google Scholar

Fried, P. A., and Watkinson, B. (1988). 12- and 24-month neurobehavioural follow-up of children prenatally exposed to marihuana, cigarettes and alcohol. Neurotoxicol Teratol, 10, 305–313.Google Scholar

Fried, P. A., Watkinson, B., Grant, A., et al. (1980). Changing patterns of soft drug use prior to and during pregnancy: A prospective study. Drug Alcohol Depend, 6, 323–343.CrossRefGoogle ScholarPubMed

Fried, P. A., Watkinson, B., and Gray, R. (1992). A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marihuana, cigarettes, and alcohol. Neurotoxicol Teratol, 14, 299–311.Google Scholar

Fried, P. A., Watkinson, B., and Gray, R. (1998). Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol, 20, 293–306.CrossRefGoogle ScholarPubMed

Fried, P. A., Watkinson, B., and Gray, R. (2003). Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol, 25, 427–436.Google Scholar

Fried, P. A., Watkinson, B., and Willan, A. (1984). Marijuana use during pregnancy and decreased length of gestation. Am J Obstet Gynecol, 150, 23–27.Google Scholar

Gianutsos, G., and Abbatiello, E. R. (1972). The effect of pre-natal cannabis sativa on maze learning ability in the rat. Psychopharmacologia, 27, 117–122.Google Scholar

Goldschmidt, L., Richardson, G. A., Cornelius, M. D., et al. (2004). Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol, 26, 521–532.CrossRefGoogle ScholarPubMed

Goldschmidt, L., Richardson, G. A., Willford, J., et al. (2008). Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Adolesc Psychiatry, 47, 254–263.Google Scholar

Goldschmidt, L., Richardson, G. A., Willford, J. A., et al. (2012). School achievement in 14-year-old youths prenatally exposed to marijuana. Neurotoxicol Teratol, 34, 161–167.Google Scholar

Grant, K. S., Petroff, R., Isoherranen, N., et al. (2018). Cannabis use during pregnancy: Pharmacokinetics and effects on child development. Pharmacol Ther, 182, 133–151.Google Scholar

Graves, B. M., Johnson, T. J., Nishida, R. T., et al. (2020). Comprehensive characterization of mainstream marijuana and tobacco smoke. Sci Rep, 10, 1–12.Google Scholar

Gray, K. A., Day, N. L., Leech, S., et al. (2005). Prenatal marijuana exposure: Effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol, 27, 439–448.CrossRefGoogle ScholarPubMed

Grzeskowiak, L. E., Grieger, J. A., Andraweera, P., et al. (2020). The deleterious effects of cannabis during pregnancy on neonatal outcomes. Med J Aust, 212, 519–524.Google Scholar

Gunn, J. K. L., Rosales, C. B., Center, K. E., et al. (2016). Prenatal exposure to cannabis and maternal and child health outcomes: A systematic review and meta-analysis. BMJ Open, 6, e009986.Google Scholar

Holloway, Z. R., Hawkey, A. B., Torres, A. K., et al. (2020). Paternal cannabis extract exposure in rats: Preconception timing effects on neurodevelopmental behavior in offspring. NeuroToxicology, 81, 180–188.Google Scholar

Hutchings, D. E., Martin, B. R., Gamagaris, Z., et al. (1989). Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci, 44, 697–701.Google Scholar

Jaddoe, V. W. V., Mackenbach, J. P., Moll, H. A., et al. (2006). The Generation R study: Design and cohort profile. Eur J Epidemiol, 21, 475–484.Google Scholar

Kapur, B. M., and Aleksa, K. (2020). What the lab can and cannot do: clinical interpretation of drug testing results. Crit Rev Clin Lab Sci, 57, 548–585.CrossRefGoogle ScholarPubMed

Ko, J. Y., Farr, S. L., Tong, V. T., et al. (2015). Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol, 213, 201.e1–201.e10.Google Scholar

Kooijman, M. N., Kruithof, C. J., van Duijn, C. M., et al. (2016). The Generation R study: Design and cohort update 2017. Eur J Epidemiol, 31, 1243–1264.Google Scholar

Leech, S. L., Richardson, G. A., Goldschmidt, L., et al. (1999). Prenatal substance exposure: Effects on attention and impulsivity of 6-year-olds. Neurotoxicol Teratol, 21, 109–118.Google Scholar

Leemaqz, S. Y., Dekker, G. A., McCowan, L. M., et al. (2016). Maternal marijuana use has independent effects on risk for spontaneous preterm birth but not other common late pregnancy complications. Reprod Toxicol, 62, 77–86.Google Scholar

Levin, E. D., Hawkey, A. B., Hall, B. J., et al. (2019). Paternal THC exposure in rats causes long-lasting neurobehavioral effects in the offspring. Neurotoxicol Teratol, 74, 106806.Google Scholar

Maia, J., Midão, L., Cunha, S. C., et al. (2019). Effects of cannabis tetrahydrocannabinol on endocannabinoid homeostasis in human placenta. Arch Toxicol, 93, 649–658.Google Scholar

Manduca, A., Servadio, M., Melancia, F., et al. (2020). Sex-specific behavioural deficits induced at early life by prenatal exposure to the cannabinoid receptor agonist WIN55, 212-2 depend on mGlu5 receptor signalling. Br J Pharmacol, 177, 449–463.CrossRefGoogle Scholar

Mereu, G., Fà, M., Ferraro, L., et al. (2003). Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci USA, 100, 4915–4920.Google Scholar

Natale, B. V., Gustin, K. N., Lee, K., et al. (2020). Δ9-tetrahydrocannabinol exposure during rat pregnancy leads to symmetrical fetal growth restriction and labyrinth-specific vascular defects in the placenta. Sci Rep, 10, 1–15.CrossRefGoogle ScholarPubMed

Niesink, R. J. M., and van Laar, M. W. (2013). Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry, 4, 130.CrossRefGoogle ScholarPubMed

O’Shea, M., and Mallet, P. E. (2005). Impaired learning in adulthood following neonatal Δ9-THC exposure. Behav Pharmacol, 16, 455–461.Google Scholar

Paul, S. E., Hatoum, A. S., Fine, J. D., et al. (2021). Associations between prenatal cannabis exposure and childhood outcomes: Results from the ABCD study. JAMA Psychiatry, 78, 64.Google Scholar

Porath, A. J., and Fried, P. A. (2005). Effects of prenatal cigarette and marijuana exposure on drug use among offspring. Neurotoxicol Teratol, 27, 267–277.CrossRefGoogle ScholarPubMed

Richardson, G. A., Goldschmidt, L., and Willford, J. (2009). Continued effects of prenatal cocaine use: Preschool development. Neurotoxicol Teratol, 31, 325–333.CrossRefGoogle ScholarPubMed

Richardson, G. A., Ryan, C., Willford, J., et al. (2002). Prenatal alcohol and marijuana exposure: Effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol, 24, 309–320.Google Scholar

Rose-Jacobs, R., Augustyn, M., Beeghly, M., et al. (2012). Intrauterine substance exposures and Wechsler Individual Achievement Test-II scores at 11 years of age. Vulnerable Child Youth Stud, 7, 186–197.Google Scholar

Rose-Jacobs, R., Soenksen, S., Appugliese, D. P., et al. (2011). Early adolescent executive functioning, intrauterine exposures and own drug use. Neurotoxicol Teratol, 33, 379–392.CrossRefGoogle ScholarPubMed

Sagheddu, C., Traccis, F., Serra, V., et al. (2021). Mesolimbic dopamine dysregulation as a signature of information processing deficits imposed by prenatal THC exposure. Prog Neuropsychopharmacol Biol Psychiatry, 105, 110128.Google Scholar

Silva, L., Zhao, N., Popp, S., et al. (2012). Prenatal tetrahydrocannabinol (THC) alters cognitive function and amphetamine response from weaning to adulthood in the rat. Neurotoxicol Teratol, 34, 63–71.Google Scholar

Singer, L. T., Nelson, S., Short, E., et al. (2008). Prenatal cocaine exposure: Drug and environmental effects at 9 years. J Pediatr, 153, 105–111.Google Scholar

Smith, A. M., Mioduszewski, O., Hatchard, T., et al. (2016). Prenatal marijuana exposure impacts executive functioning into young adulthood: An fMRI study. Neurotoxicol Teratol, 58, 53–59.Google Scholar

Sonon, K. E., Richardson, G. A., Cornelius, J. R., et al. (2015). Prenatal marijuana exposure predicts marijuana use in young adulthood. Neurotoxicol Teratol, 47, 10–15.Google Scholar

Szutorisz, H., DiNieri, J. A., Sweet, E., et al. (2014). Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. Neuropsychopharmacology, 39, 1315–1323.Google Scholar

Szutorisz, H., Egervári, G., Sperry, J., et al. (2016). Cross-generational THC exposure alters the developmental sensitivity of ventral and dorsal striatal gene expression in male and female offspring. Neurotoxicol Teratol, 58, 107–114.Google Scholar

Torres, C. A., Medina-Kirchner, C., O’Malley, K. Y., et al. (2020). Totality of the evidence suggests prenatal cannabis exposure does not lead to cognitive impairments: A systematic and critical review. Front Psychol, 11, 816.Google Scholar

Tortoriello, G., Morris, C. V., Alpar, A., et al. (2014). Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J, 33, 668–685.Google Scholar

Trezza, V., Cuomo, V., and Vanderschuren, L. J. M. J. (2008). Cannabis and the developing brain: Insights from behavior. Eur J Pharmacol, 585, 441–452.Google Scholar

Volk, D. W., and Lewis, D. A. (2016). The role of endocannabinoid signaling in cortical inhibitory neuron dysfunction in schizophrenia. Biol Psychiatry, 79, 595–603.Google Scholar

Volkow, N. D., Fowler, J. S., Wang, G. J., et al. (2007). Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications. Arch Neurol, 64, 1575–1579.Google Scholar

Volkow, N. D., Han, B., Compton, W. M., et al. (2019). Self-reported medical and nonmedical cannabis use among pregnant women in the United States. JAMA, 322, 167–169.Google Scholar

Wang, X., Dow-Edwards, D., Anderson, V., et al. (2004). In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry, 56, 909–915.Google Scholar

Watson, C. T., Szutorisz, H., Garg, P., et al. (2015). Genome-wide DNA methylation profiling reveals epigenetic changes in the rat nucleus accumbens associated with cross-generational effects of adolescent THC exposure. Neuropsychopharmacology, 40, 2993–3005.Google Scholar

Weimar, H. V., Wright, H. R., Warrick, C. R., et al. (2020). Long-term effects of maternal cannabis vapor exposure on emotional reactivity, social behavior, and behavioral flexibility in offspring. Neuropharmacology, 179, 108288.Google Scholar

Wu, C.-S., Jew, C. P., and Lu, H.-C. (2011). Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol, 6, 459–480.CrossRefGoogle ScholarPubMed

Yao, J. L., He, Q. Z., Liu, M., et al. (2018). Effects of Δ(9)-tetrahydrocannabinol (THC) on human amniotic epithelial cell proliferation and migration. Toxicology, 394, 19–26.CrossRefGoogle Scholar

Young-Wolff, K. C., Adams, S. R., Padon, A., et al. (2021). Association of cannabis retailer proximity and density with cannabis use among pregnant women in Northern California after legalization of cannabis for recreational use. JAMA Netw Open, 4, e210694.CrossRefGoogle ScholarPubMed

Young-Wolff, K. C., Sarovar, V., Tucker, L. Y., et al. (2020). Validity of self-reported cannabis use among pregnant females in Northern California. J Addict Med, 14, 287–292.Google Scholar

Zammit, S., Thomas, K., Thompson, A., et al. (2009). Maternal tobacco, cannabis and alcohol use during pregnancy and risk of adolescent psychotic symptoms in offspring. Br J Psychiatry, 195, 294–300.Google Scholar

Zurolo, E., Iyer, A. M., Spliet, W. G. M., et al. (2010). CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies. Neuroscience, 170, 28–41.Google Scholar

Aebi, M. F., and Tiago, M. M. (2020). Prisons and prisoners in Europe in pandemic times: An evaluation of the short-term impact of the COVID-19 on prison populations. Universite de Lausanne (Junio): 1–17.Google Scholar

Afifi, T. O., Henriksen, C. A., Asmundson, G. J. G., et al. (2012). Victimization and perpetration of intimate partner violence and substance use disorders in a nationally representative sample. J Nervous Mental Dis, 200, 684–691.Google Scholar

Amaro, H., Fried, L. E., Cabral, H., et al. (1990). Violence during pregnancy and substance use. Am J Public Health, 80, 575–579.Google Scholar

van de Baan, F. C., Montanari, L., Royuela, L., et al. (2022). Prevalence of illicit drug use before imprisonment in Europe: Results from a comprehensive literature review. Drugs Educ Prevent Policy, 29, 1–12.Google Scholar

Blitstein, J. L., Murray, D. M., Lytle, L. A., et al. (2005). Predictors of violent behavior in an early adolescent cohort: Similarities and differences across genders. Health Educ Behav, 32, 175–194.CrossRefGoogle Scholar

Bloomfield, M. A. P., Hindocha, C., Green, S. F., et al. (2019). The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacol Ther, 195, 132–161.Google Scholar

Brook, J. S., Lee, J. Y., Finch, S. J., et al. (2014). Developmental trajectories of marijuana use from adolescence to adulthood: Relationship with using weapons including guns. Aggress Behav, 40, 229–237.Google Scholar

Bujarski, S. J., McDaniel, C. E., Lewis, S. F., et al. (2016). Past-month marijuana use is associated with self-reported violence among trauma-exposed adolescents. J Child Adolesc Subst Abuse, 26, 111–118.Google Scholar

Crane, C. A., Oberleitner, L. M. S., Devine, S., et al. (2014). Substance use disorders and intimate partner violence perpetration among male and female offenders. Psychol Violence, 4, 322–333.Google Scholar

Dellazizzo, L., Potvin, S., Beaudoin, M., et al. (2019). Cannabis use and violence in patients with severe mental illnesses: A meta-analytical investigation. Psychiatry Res, 274, 42–48.Google Scholar

Dellazizzo, L., Potvin, S., Dou, B. Y., et al. (2020). Association between the use of cannabis and physical violence in youths: A meta-analytical investigation. Am J Psychiatry, 177, 619–626.Google Scholar

Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. The Lancet Psychiatry 6, 427–436.Google Scholar

ESPAD. (2019). Results from the European School Survey Project on Alcohol and Other Drugs. Available at: https://europa.eu/!Xy37DU. Last accessed 23 November 2021.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. (2021). European Drug Report Trends and Developments. Lisbon: EMCDDA.Google Scholar

Fazel, S., Gulati, G., Linsell, L., et al. (2009). Schizophrenia and violence: Systematic review and meta-analysis. PLoS Med, 6, e1000120.Google Scholar

Gibbs, M., Winsper, C., Marwaha, S., et al. (2015). Cannabis use and mania symptoms: A systematic review and meta-analysis. J Affect Disord, 171, 39–47.Google Scholar

Grest, C. V., Amaro, H., and Unger, J. (2018). Longitudinal predictors of intimate partner violence perpetration and victimization in Latino emerging adults. J Youth Adolesc, 47, 560–574.Google Scholar

Krug, E. G., Dahlberg, L. L., Mercy, J. A., et al. (2002). World Report on Violence and Health. Geneva: World Health Organization.CrossRefGoogle ScholarPubMed

Lim, J. Y., and Lui, C. K. (2016). Longitudinal associations between substance use and violence in adolescence through adulthood. J Social Work Pract Addict, 16, 72–92.Google Scholar

López-Pelayo, H., Batalla, A., Balcells, M. M., et al. (2015). Assessment of cannabis use disorders: A systematic review of screening and diagnostic instruments. Psychol Med, 45, 1121–1133.Google Scholar

Miettunen, J., Murray, G. K., Jones, P. B., et al. (2014). Longitudinal associations between childhood and adulthood externalizing and internalizing psychopathology and adolescent substance use. Psychol Med, 44, 1727–1738.Google Scholar

Moore, T. H., Zammit, S., Lingford-Hughes, A., et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370, 319–328.Google Scholar

Moore, T. M., and Stuart, G. L. (2005). A review of the literature on marijuana and interpersonal violence. Aggress Violent Behav, 10, 171–192.Google Scholar

Morojele, N. K., and Brook, J. S. (2006). Substance use and multiple victimisation among adolescents in South Africa. Addict Behav, 31, 1163–1176.Google Scholar

Murray, R. M., and Hall, W. (2020). Will legalization and commercialization of cannabis use increase the incidence and prevalence of psychosis? JAMA Psychiatry, 77, 777–778.Google Scholar

Pedersen, W., and Skardhamar, T. (2010). Cannabis and crime: Findings from a longitudinal study. Addiction, 105, 109–118.Google Scholar

Schlienz, N. J., Budney, A. J., Lee, D. C., et al. (2017). Cannabis withdrawal: A review of neurobiological mechanisms and sex differences. Curr Addict Rep, 4, 75–81.Google Scholar

Silva, R. J. D. S., Soares, N. M. M., and Cabral De Oliveira, A. C. (2014). Factors associated with violent behavior among adolescents in northeastern Brazil. Sci World J, 2014, 863918.Google Scholar

Smith, P. H., Homish, G. G., Leonard, K. E., et al. (2013). Marijuana withdrawal and aggression among a representative sample of U.S. marijuana users. Drug Alcohol Depend, 132, 63–68.Google Scholar

Smith, P. H., Homish, G. G., Lorraine Collins, R., et al. (2014). Couples’ marijuana use is inversely related to their intimate partner violence over the first 9 years of marriage. Psychol Addict Behav, 28, 734–742.Google Scholar

Stuart, A., and Rich, J. D. J. (eds.) (2018). Drug Use in Prisoners: Epidemiology, Implications, and Policy Responses. Oxford: Oxford University Press.Google Scholar

Stuart, H. (2003). Violence and mental illness: An overview. World Psychiatry, 2, 121.Google Scholar

Testa, M., Livingston, J. A., and Leonard, K. E. (2003). Women’s substance use and experiences of intimate partner violence: A longitudinal investigation among a community sample. Addict Behav, 28, 1649–1664.Google Scholar

United Nation Office on Drugs and Crime. (2019). UNODC World Drug Report 2019. Available at: https://wdr.unodc.org/wdr2019/index.html. Last accessed 3 November 2022.Google Scholar

World Drug Report. (2021). UNODC World Drug Report 2021. Available at: www.unodc.org/unodc/en/data-and-analysis/wdr2021.html. Last accessed 23 November 2021.Google Scholar

World Health Organization. (2016). Prevention of Violence: Public Health Priority. Available at: https://apps.who.int/iris/handle/10665/179463. Last accessed 24 November 2021.Google Scholar

Agrawal, A., Pergadia, M. L., Saccone, S. F., et al. (2008). An autosomal linkage scan for cannabis use disorders in the nicotine addiction genetics project. Arch Gen Psychiatry, 65, 713–721.Google Scholar

Ahmadi, J., Kampman, K., Dackis, C., et al. (2008). Cocaine withdrawal symptoms identify ‘type B’ cocaine-dependent patients. Am J Addict, 17, 60–64.Google Scholar

Allsop, D. J., Copeland, J., Norberg, M. M., et al. (2012). Quantifying the clinical significance of cannabis withdrawal. PLoS ONE, 7, 1–12.Google Scholar

Allsop, D. J., Lintzeris, N., Copeland, J., et al. (2015). Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clin Pharmacol Therap, 97, 571–574.Google Scholar

Allsop, D. J., Norberg, M. M., Copeland, J., et al. (2011). The cannabis withdrawal scale development: Patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend, 119, 123–129.Google Scholar

American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, DC: American Psychiatric Association.Google Scholar

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th Ed.). Arlington, VA: American Psychiatric Publishing.Google Scholar

Arendt, M., Rosenberg, R., Foldager, L., et al. (2007). Withdrawal symptoms do not predict relapse among subjects treated for cannabis dependence. Am J Addict, 16, 461–467.CrossRefGoogle Scholar

Baker, T. B., Piper, M. E., McCarthy, D. E., et al. (2004). Addiction motivation reformulated: An affective processing model of negative reinforcement. Psychol Rev, 111, 33–51.Google Scholar

Balter, R. E., Cooper, Z. D., and Haney, M. (2014). Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep, 1, 137–143.Google Scholar

Bedi, G., Cooper, Z. D., and Haney, M. (2013). Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol, 18, 872–881.Google Scholar

Benyamina, A., Lecacheux, M., Blecha, L., et al. (2008). Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Rev Neurother, 8, 479–491.Google Scholar

Boggs, D. L., Kelly, D. L., Liu, F., et al. (2013). Cannabis withdrawal in chronic cannabis users with schizophrenia. J Psychiatric Res, 47, 240–245.Google Scholar

Bolla, K. I., Lesage, S. R., Gamaldo, C. E., et al. (2008). Sleep disturbance in heavy marijuana users. Sleep, 31, 901–908.Google Scholar

Bonn-Miller, M. O., Boden, M. T., Bucossi, M. M., et al. (2014). Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse, 40, 23–30.Google Scholar

Bonn-Miller, M. O., Vujanovic, A., Twohig, M. P., et al. (2010). Posttraumatic stress symptom severity and marijuana use coping motives: A test of the mediating role of non-judgmental acceptance within a trauma-exposed community sample. Mindfulness, 1, 98–106.Google Scholar

Bonn-Miller, M. O., and Zvolensky, M. J. (2009). An evaluation of the nature of marijuana use and its motives among young adult active users. Am J Addict, 18, 409–416.Google Scholar

Bowen, S., Chawla, N., and Marlatt, G. A. (2011). Mindfulness-based Relapse Prevention for Addictive Behaviors: A Clinician’s Guide. New York: Guilford Press.Google Scholar

Bowen, S., Witkiewitz, K., Clifasefi, S. L., et al. (2014). Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: A randomized clinical trial. JAMA Psychiatry, 71, 547–556.Google Scholar

Buckner, J. D., and Zvolensky, M. J. (2014). Cannabis and related impairment: The unique roles of cannabis use to cope with social anxiety and social avoidance. Am J Addict, 23, 598–603.Google Scholar

Buckner, J. D., Zvolensky, M. J., Schmidt, N. B., et al. (2014). Integrated cognitive behavioral therapy for cannabis use and anxiety disorders: Rationale and development. Addict Behav, 39, 495–496.Google Scholar

Budney, A. J. (2006). Are specific dependence criteria necessary for different substances: How can research on cannabis inform this issue? Addiction, 101, 125–133.Google Scholar

Budney, A. J., Borodovsky, J.T. and Knapp, A. A. (2019a). Clinical manifestations of cannabis use disorder. In Montoya, I. D., and Weiss, S. R. B. (eds.) Cannabis Use Disorders (pp. 85–91). Cham: Springer International Publishing.Google Scholar

Budney, A. J., Higgins, S. T., Radanovich, K. J., et al. (2000). Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol, 68, 1051–1061.Google Scholar

Budney, A. J., and Hughes, J. R. (2006). The cannabis withdrawal syndrome. Curr Opin Psychiatry, 19, 233–238.Google Scholar

Budney, A. J., Hughes, J. R., Moore, M. A., et al. (2001). Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry, 58, 917–924.Google Scholar

Budney, A. J., Moore, B. A., Rocha, L. A., et al. (2006). Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol, 74, 307–316.Google Scholar

Budney, A. J., Moore, B. A., and Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry, 161, 1967–1977.Google Scholar

Budney, A. J., Moore, B. A., Vandrey, R. G., et al. (2003). The time course and significance of cannabis withdrawal. J Abnormal Psychol, 112, 393–402.Google Scholar

Budney, A. J., Novy, P. L., and Hughes, J. R. (1999). Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction, 94, 1311–1322.Google Scholar

Budney, A. J., Radonovich, K. J., Higgins, S. T., et al. (1998). Adults seeking treatment for marijuana dependence: A comparison with cocaine-dependent treatment seekers. Exp Clin Psychopharmacol, 6, 419–426.Google Scholar

Budney, A. J., Roffman, R., Stephens, R. S., et al. (2007a). Marijuana dependence and its treatment. Addict Sci Clin Pract, 4, 4–16.Google Scholar

Budney, A. J., Sofis, M. J., and Borodovsky, J. T. (2019b). An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. Eur Arch Psychiatry Clin Neurosci, 269, 73–86.Google Scholar

Budney, A. J., Vandrey, R. G., Hughes, J. R., et al. (2007b). Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend, 86, 22–29.Google Scholar

Budney, A. J., Vandrey, R. G., Hughes, J. R., et al. (2008). Comparison of cannabis and tobacco withdrawal: Severity and contribution to relapse. J Subst Abuse Treat, 35, 362–368.Google Scholar

Budney, A. J., Vandrey, R. G., and Stanger, C. (2010). Intervenções farmacológica e psicossocial para os distúrbios por uso da cannabis. Revista Brasileira de Psiquiatria, 32, 546–555.Google Scholar

Carroll, K. M., Easton, E. J., Nich, C., et al. (2006). The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. J Consult Clin Psychol, 74, 955–966.Google Scholar

Chandra, S., Radwan, M. M., Majumdar, C. G., et al. (2019). New trends in cannabis potency in USA and Europe during the last decade (2008–2017). Eur Arch Psychiatry Clin Neurosci, 269, 5–15.Google Scholar

Chauchard, E., Goncharov, O., Krupitsky, E., et al. (2014). Cannabis withdrawal in patients with and without opioid dependence. Subst Abuse, 35, 230–234.Google Scholar

Compton, W. M., Saha, T. D., Conway, K. P., et al. (2009). The role of cannabis use within a dimensional approach to cannabis use disorders. Drug Alcohol Depend, 100, 221–227.Google Scholar

Cooper, Z. D. (2016). Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal. Curr Psychiatry Rep, 18, 52.Google Scholar

Cooper, Z. D., and Haney, M. (2008). Cannabis reinforcement and dependence: Role of the cannabinoid CB1 receptor: Cannabis dependence. Addict Biol, 13, 188–195.Google Scholar

Cooper, Z. D., and Haney, M. (2014). Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend, 136, 85–91.Google Scholar

Copeland, J., Swift, W., and Rees, V. (2001). Clinical profile of participants in a brief intervention program for cannabis use disorder. J Subst Abuse Treat, 20, 45–52.Google Scholar

Copersino, M. L., Boyd, S. J., Tashkin, D. P., et al. (2010). Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal. Am J Drug Alcohol Abuse, 36, 311–319.Google Scholar

Cornelius, J. R., Chung, T., Martin, C., et al. (2008). Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict Behav, 33, 1500–1505.Google Scholar

Crowley, T. J., Macdonald, M. J., Whitmore, E. A., et al. (1998). Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct disorder symptoms and substance use disorders. Drug Alcohol Depend, 50, 27–37.Google Scholar

D’Souza, D. C., Cortes-Briones, J., Creatura, G., et al. (2019). Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: A double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry, 6, 35–45.Google Scholar

D’Souza, D. C., Cortes-Briones, J. A., Ranganathan, M., et al. (2016). Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging, 1, 60–67.Google Scholar

Davis, M. L., Powers, M. B., Handelsman, P., et al. (2015). Behavioral therapies for treatment-seeking cannabis users: A meta-analysis of randomized controlled trials. Eval Health Prof, 38, 94–114.Google Scholar

Dawes, G. M., Sitharthan, T., Conigrave, K. M., et al. (2011). Patients admitted for inpatient cannabis detoxification: Withdrawal symptoms and impacts of common comorbidities. J Subst Use, 16, 392–405.Google Scholar

Dennis, M. L., Funk, R., Harrington Godley, S., et al. (2004). Cross-validation of the alcohol and cannabis use measures in the Global Appraisal of Individual Needs (GAIN) and Timeline Followback (TLFB; Form 90) among adolescents in substance abuse treatment. Addiction, 99, 120–128.Google Scholar

Dutra, L., Stathopoulou, G., Basden, S. L., et al. (2008). A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry, 165, 179–187.Google Scholar

Ehlers, C. L., Gizer, I. R., Vieten, C., et al. (2010a). Cannabis dependence in the San Francisco Family Study: Age of onset of use, DSM-IV symptoms, withdrawal, and heritability. Addict Behav, 35, 102–110.Google Scholar

Ehlers, C. L., Gizer, I. R., Vieten, C., et al. (2010b). Linkage analyses of cannabis dependence, craving, and withdrawal in the San Francisco family study. Am J Med Genet B Neuropsychiatr Genet, 153B, 802–811.Google Scholar

ElSohly, M. A., Mehmedic, Z., Foster, S., et al. (2016). Changes in cannabis potency over the last 2 decades (1995–2014): Analysis of current data in the United States. Biol Psychiatry, 79, 613–619.CrossRefGoogle ScholarPubMed

Farris, S. G., Metrik, J., Bonn-Miller, M. O., et al. (2016). Anxiety sensitivity and distress intolerance as predictors of cannabis dependence symptoms, problems, and craving: The mediating role of coping motives. J Stud Alcohol Drugs, 77, 889–897.Google Scholar

Freeman, D., Brugha, T., Meltzer, H., et al. (2010). Persecutory ideation and insomnia: Findings from the second British National Survey of Psychiatric Morbidity. J Psychiatr Res, 44, 1021–1026.Google Scholar

Freeman, T. P., Groshkova, T., Cunningham, A., et al. (2019). Increasing potency and price of cannabis in Europe, 2006–16: Cannabis in Europe. Addiction, 114, 1015–1023.Google Scholar

Freeman, T. P., Hindocha, C., Baio, G., et al. (2020). Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry, 7, 865–874.Google Scholar

Garcia, A. N., and Salloum, I. M. (2015). Polysomnographic sleep disturbances in nicotine, caffeine, alcohol, cocaine, opioid, and cannabis use: A focused review. Am J Addict, 24, 590–598.Google Scholar

Gates, P., Albertella, L., and Copeland, J. (2016). Cannabis withdrawal and sleep: A systematic review of human studies. Subst Abuse, 37, 255–269.Google Scholar

Glozier, N., Martiniuk, A., Patton, G., et al. (2010). Short sleep duration in prevalent and persistent psychological distress in young adults: The DRIVE study. Sleep, 33, 1139–1145.Google Scholar

Gorelick, D. A., Levin, K. H., Copersino, M. L., et al. (2012). Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend, 123, 141–147.Google Scholar

Grant, B. F., Goldstein, R. B., Saha, T. D., et al. (2016). Epidemiology of DSM-5 drug use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions–III. JAMA Psychiatry, 73, 39.Google Scholar

Gray, K. M., Carpenter, M. J., Baker, N. L., et al. (2012). A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry, 169, 805–812.Google Scholar

Gray, K. M., Sonne, S. C., McClure, E. A., et al. (2017). A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend, 177, 249–257.Google Scholar

Greene, M. C., and Kelly, J. F. (2014). The prevalence of cannabis withdrawal and its influence on adolescents’ treatment response and outcomes: A 12-month prospective investigation. J Addict Med, 8, 359–367.Google Scholar

Haney, M. (2005). The marijuana withdrawal syndrome: Diagnosis and treatment. Curr Psychiatry Rep, 7, 360–366.Google Scholar

Haney, M., Cooper, Z. D., Bedi, G., et al. (2013). Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology, 38, 1557–1565.Google Scholar

Haney, M., Hart, C. L., Vosburg, S. K., et al. (2004). Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharmacology, 29, 158–170.Google Scholar

Haney, M., Hart, C. L., Vosburg, S. K., et al. (2008). Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology, 197, 157–168.Google Scholar

Haney, M., and Spealman, R. (2008). Controversies in translational research: Drug self-administration. Psychopharmacology, 199, 403–419.Google Scholar

Haney, M., Ward, A. S., Comer, S. D., et al. (1999). Abstinence symptoms following oral THC administration to humans. Psychopharmacology, 141, 385–394.Google Scholar

Hart, C. L. (2005). Increasing treatment options for cannabis dependence: A review of potential pharmacotherapies. Drug Alcohol Depend, 80, 147–159.Google Scholar

Harte-Hargrove, L. C., and Dow-Edwards, D. L. (2012). Withdrawal from THC during adolescence: Sex differences in locomotor activity and anxiety. Behav Brain Res, 231, 48–59.Google Scholar

Hasin, D. S., Kerridge, B. T., Saha, T. D., et al. (2016). Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: Findings from the national epidemiologic survey on alcohol and related conditions-III. Am J Psychiatry, 173, 588–599.Google Scholar

Hasin, D. S., Keyes, K. M., Alderson, D., et al. (2008). Cannabis withdrawal in the United States: Results from NESARC. J Clin Psychiatry, 69, 1354–1363.Google Scholar

Haughey, H. M., Marshall, E., Schacht, J. P., et al. (2008). Marijuana withdrawal and craving: Influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction, 103, 1678–1686.Google Scholar

Herrmann, E. S., Weerts, E. M., and Vandrey, R. (2015). Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Exp Clin Psychopharmacol, 23, 415–421.Google Scholar

Hesse, M., and Thylstrup, B. (2013). Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers. BMC Psychiatry, 13, 1–11.Google Scholar

Hirhoven, J., Goodwin, R. S., Li, C.-T., et al. (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry, 17, 642–649.Google Scholar

Hughes, J. R., Higgins, S. T., and Bickel, W. K. (1994). Nicotine withdrawal versus other drug withdrawal syndromes: Similarities and dissimilarities. Addiction, 89, 1461–1470.Google Scholar

Johnson, K., Mullin, J. L., Marshall, E. C., et al. (2010). Exploring the mediational role of coping motives for marijuana use in terms of the relation between anxiety sensitivity and marijuana dependence. Am J Addict, 19, 277–282.Google Scholar

Kadden, R. M., Litt, M. D., Kabela-Cormier, E., et al. (2007). Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav, 32, 1220–1236.Google Scholar

Koob, G. F., and Volkow, N. D. (2016). Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry, 3, 760–773.Google Scholar

Kosiba, J. D., Maisto, S. A., and Ditre, J. W. (2019). Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis. Soc Sci Med, 233, 181–192.Google Scholar

Kouri, E. M., and Pope, H. G. Jr. (2000). Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol, 8, 483–492.Google Scholar

Ledent, C., Valverde, O., Cossu, G., et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 283, 401–404.Google Scholar

Levin, F. R., Mariani, J. J., Brooks, D. J., et al. (2011). Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend, 116, 142–150.Google Scholar

Levin, K. H., Copersino, M. L., Heishman, S. J., et al. (2010). Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend, 111, 120–127.Google Scholar

Lichtman, A. H., and Martin, B. R. (2002). Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol, 42, 20S–27S.Google Scholar

Lichtman, A. H., and Martin, B. R. (2006). Understanding the phamacology and physiology of cannabis dependence. In Cannabis Dependence: Its Nature, Consequences, and Treatment (pp. 37–57). Cambridge: Cambridge University Press.Google Scholar

Lin, L. A., Ilgen, M. A., Jannausch, M., et al. (2016). Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample. Addict Behav, 61, 99–103.Google Scholar

Lintzeris, N., Bhardwaj, A., Mills, L., et al. (2019). Nabiximols for the treatment of cannabis dependence: A randomized clinical trial. JAMA Intern Med, 179, 1242–1253.Google Scholar

Livne, O., Shmulewitz, D., Lev-Ran, S., et al. (2019). DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Drug Alcohol Depend, 195, 170–177.Google Scholar

Lynskey, M. T., and Agrawal, A. (2007). Psychometric properties of DSM assessments of illicit drug abuse and dependence: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol Med, 37, 1345–1355.Google Scholar

Macfarlane, V., and Christie, G. (2015). Synthetic cannabinoid withdrawal: A new demand on detoxification services: Synthetic cannabinoid detoxification. Drug Alcohol Rev, 34, 147–153.Google Scholar

Marusich, J. A., Lefever, T. W., Antonazzo, K. R., et al. (2014). Evaluation of sex differences in cannabinoid dependence. Drug Alcohol Depend, 137, 20–28.Google Scholar

Mason, B. J., Crean, R., Goodell, V., et al. (2012). A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology, 37, 1689–1698.Google Scholar

Mednick, S. C., Christakis, N. A., and Fowler, J. H. (2010). The spread of sleep loss influences drug use in adolescent social networks. PLoS ONE, 5, e9775.Google Scholar

Meier, M. H. (2017). Associations between butane hash oil use and cannabis-related problems. Drug Alcohol Depend, 179, 25–31.Google Scholar

Metrik, J., Bassett, S. S., Aston, E. R., et al. (2018). Medicinal versus recreational cannabis use among returning veterans. Transl Issues Psychol Sci, 4, 6–20.Google Scholar

Metrik, J., Farris, S. G., Aston, E. R., et al. (2017). Development and initial validation of a marijuana cessation expectancies questionnaire. Drug Alcohol Depend, 177, 163–170.Google Scholar

Metrik, J., Jackson, K., Bassett, S. S., et al. (2016). The mediating roles of coping, sleep, and anxiety motives in cannabis use and problems among returning veterans with PTSD and MDD. Psychol Addict Behav, 30, 743–754.Google Scholar

Metrik, J., Kahler, C. W., McGeary, J. E., et al. (2011). Acute effects of marijuana smoking on negative and positive affect. J Cogn Psychother, 25, 10.1891/0889-8391.25.1.31.Google Scholar

Metrik, J., and Ramesh, D. (2018). Cannabis use disorder. In MacKillop, J., Kenna, G. A., Leggio, L., et al. (eds.) Integrating Psychological and Pharmacological Treatments for Addictive Disorders: An Evidence-Based Guide (pp. 150–171). New York: Routledge.Google Scholar

Mikulich, S. K., Hall, S. K., Whitmore, E. A., et al. (2001). Concordance between DSM-III-R and DSM-IV diagnoses of substance use disorders in adolescents. Drug Alcohol Depend, 61, 237–248.Google Scholar

Milin, R., Manion, I., Dare, G., et al. (2008). Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: A pilot study. J Am Acad Child Adolesc Psychiatry, 47, 174–179.Google Scholar

Mokrysz, C., Freeman, T. P., Korkki, S., et al. (2016). Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Transl Psychiatry, 6, 1–10.Google Scholar

Monti, P. M., Colby, S. M., and O’Leary, T. A. (eds.) (2001). Adolescents, Alcohol, and Substance Abuse: Reaching Teens through Brief Interventions. New York: Guilford Press.Google Scholar

National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.Google Scholar

Nicholson, A. N., Turner, C., Stone, B. M., et al. (2004). Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol, 24, 305–313.Google Scholar

Osborn, L. A., Lauritsen, K. J., Cross, N., et al. (2015). Self-medication of somatic and psychiatric conditions using botanical marijuana. J Psychoactive Drugs, 47, 345–350.Google Scholar

Oshri, A., Rogosch, F. A., Burnette, M. L., et al. (2011). Developmental pathways to adolescent cannabis abuse and dependence: Child maltreatment, emerging personality, and internalizing versus externalizing psychopathology. Psychol Addict Behav, 25, 634–644.Google Scholar

Pacek, L. R., Herrmann, E. S., Smith, M. T., et al. (2017). Sleep continuity, architecture and quality among treatment-seeking cannabis users: An in-home, unattended polysomnographic study. Exp Clin Psychopharmacol, 25, 295–302.Google Scholar

Pertwee, R. G. (2005). Pharmacological actions of cannabinoids. Hbk Exp Pharmacol, 168, 1–51.Google Scholar

Potter, C. M., Vujanovic, A. A., Marshall-Berenz, E. C., et al. (2011). Posttraumatic stress and marijuana use coping motives: The mediating role of distress tolerance. J Anxiety Disord, 25, 437–443.Google Scholar

Prendergast, M., Podus, D., Finney, J., et al. (2006). Contingency management for treatment of substance use disorders: A meta-analysis. Addiction, 101, 1546–1560.Google Scholar

Preuss, U. W., Watzke, A. B., Zimmermann, J., et al. (2010). Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients. Drug Alcohol Depend, 106, 133–141.Google Scholar

Rabin, R. A., Kozak, K., Zakzanis, K. K., et al. (2018). Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophr Res, 194, 55–61.Google Scholar

Ramesh, D., and Haney, M. (2015). Treatment of cannabis use disorders. In el-Guebaly, N., Carrà, G., and Galanter, M. (eds.) Textbook of Addiction Treatment: International Perspectives (pp. 367–380). Milan: Springer Milan.Google Scholar

Reinarman, C., Nunberg, H., Lanthier, F., et al. (2011). Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs, 43, 128–135.Google Scholar

Schacht, J. P., Selling, R. E., and Hutchison, K. E. (2009). Intermediate cannabis dependence phenotypes and the FAAH C385A variant: An exploratory analysis. Psychopharmacology, 203, 511–517.Google Scholar

Schlienz, N. J., Budney, A. J., Lee, D. C., et al. (2017). Cannabis withdrawal: A review of neurobiological mechanisms and sex differences. Curr Addict Rep, 4, 75–81.Google Scholar

Schlienz, N. J., and Vandrey, R. (2019). Cannabis withdrawal. In Montoya, I. D., and Weiss, S. R. B. (eds.) Cannabis Use Disorders (pp. 93–102). Cham: Springer International Publishing.Google Scholar

Schofield, D., Tennant, C., Nash, L., et al. (2006). Reasons for cannabis use in psychosis. Aust NZ J Psychiatry, 40, 570–574.Google Scholar

Schuster, R. M., Fontaine, M., Nip, E., et al. (2017). Prolonged cannabis withdrawal in young adults with lifetime psychiatric illness. Prevent Med, 104, 40–45.Google Scholar

Segal, Z. V., Teasdale, J. D., and Williams, J. M. G. (2004). Mindfulness-based cognitive therapy: Theoretical rationale and empirical status. In Hayes, S. C., Follette, V. M., and Linehan, M. M. (eds.) Mindfulness and Acceptance: Expanding the Cognitive-Behavioral Tradition (pp. 45–65). New York: Guilford Press.Google Scholar

Sherman, B. J., Baker, N. L., and McRae-Clark, A. L. (2017). Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. Psychiatry Res, 249, 318–320.Google Scholar

Simons, J. S., Gaher, R. M., Correia, C. J., et al. (2005). An affective-motivational model of marijuana and alcohol problems among college students. Psychol Addict Behav, 19, 326–334.Google Scholar

Stanger, C., Budney, A. J., Kamon, J. L., et al. (2009). A randomized trial of contingency management for adolescent marijuana abuse and dependence. Drug Alcohol Depend, 105, 240–247.Google Scholar

Steinberg, K. L., Roffman, R. A., Carroll, K. M., et al. (2005). Brief Counseling for Marijuana Dependence: A Manual for Treating Adults. Baltimore, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration.Google Scholar

Stephens, R. S., Babor, T. F., Kadden, R., et al. (2002). The marijuana treatment project: Rationale, design, and participant characteristics. Addiction, 97, 109S–124S.Google Scholar

Trigo, J. M., Soliman, A., Quilty, L. C., et al. (2018). Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS ONE, 13, e0190768–e0190768.Google Scholar

Tringale, R., and Jensen, C. (2011). Cannabis and Insomnia: Patients commonly report that use of cannabis reduces the time it takes them to fall asleep: Whether or not insomnia was the complaint with which they presented. O’Shaughnessy’s, Autumn, 31–32.Google Scholar

Vandrey, R. G., Budney, A. J., Hughes, J. R., et al. (2008). A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend, 92, 48–54.Google Scholar

Vandrey, R., Budney, A. J., Kamon, J. L., et al. (2005). Cannabis withdrawal in adolescent treatment seekers. Drug Alcohol Depend, 78, 205–210.Google Scholar

Vandrey, R., and Haney, M. (2009). Pharmacotherapy for cannabis dependence: How close are we? CNS Drugs, 23, 543–553.Google Scholar

Verweij, K .J. H., Agrawal, A., Nat, N. O., et al. (2013). A genetic perspective on the proposed inclusion of cannabis withdrawal in DSM-5. Psychol Med, 43, 1713–1722.Google Scholar

Vorspan, F., Guillem, E., Bloch, V., et al. (2010). Self-reported sleep disturbances during cannabis withdrawal in cannabis-dependent outpatients with and without opioid dependence. Sleep Med, 11, 499–500.Google Scholar

Walsh, Z., Gonzalez, R., Crosby, K., et al. (2017). Medical cannabis and mental health: A guided systematic review. Clin Psychol Rev, 51, 15–29.Google Scholar

Weinberger, A. H., Desai, R. A., and McKee, S. A. (2010). Nicotine withdrawal in US smokers with current mood, anxiety, alcohol use, and substance use disorders. Drug Alcohol Depend, 108, 7–12.Google Scholar

Wiesbeck, G. A., Schuckit, M. A., Kalmijn, J. A., et al. (1996). An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction, 91, 1469–1478.Google Scholar

Wong, M. M., Brower, K. J., and Zucker, R. A. (2009). Childhood sleep problems, early onset of substance use and behavioral problems in adolescence. Sleep Med, 10, 787–796.Google Scholar

World Health Organization. (2018). International Classification of Diseases for Mortality and Morbidity Statistics (11th Revision). Geneva: World Health Organization.Google Scholar

Young, S. E., Corley, R. P., Stallings, M. C., et al. (2002). Substance use, abuse and dependence in adolescence: Prevalence, symptom profiles and correlates. Drug Alcohol Depend, 68, 309–322.Google Scholar

Albrecht, D. S., Skosnik, P. D., Vollmer, J. M., et al. (2013). Striatal D2/D3 receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend, 128, 52–57.Google Scholar

Allsop, D. J., Copeland, J., Lintzeris, N., et al. (2014). Nabiximols as an agonist replacement therapy during cannabis withdrawal: A randomized clinical trial. JAMA Psychiatry, 71, 281–291.Google Scholar

American Psychiatric Association. (2013). DSM-5 diagnostic classification. In Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.Google Scholar

Anthony, J. C., Warner, L. A., and Kessler, R. C. (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol, 2, 244–268.Google Scholar

Arterberry, B. J., Padovano, H. T., Foster, K. T., et al. (2019). Higher average potency across the United States is associated with progression to first cannabis use disorder symptom. Drug Alcohol Depend, 195, 186–192.Google Scholar

Bahji, A., Meyyappan, A. C., Hawken, E. R., et al. (2021). Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis. Int J Drug Policy, 97, 103295.CrossRefGoogle ScholarPubMed

Blakemore, S. J., and Choudhury, S. (2006). Development of the adolescent brain: Implications for executive function and social cognition. J Child Psychol Psychiatry, 47, 296–312.Google Scholar

Bloomfield, M. A. P., Morgan, C. J., Egerton, A., et al. (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol psychiatry, 75, 470–478.Google Scholar

Budney, A. J., Sofis, M. J., and Borodovsky, J. T. (2019). An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. Eur Arch Psychiatry Clin Neurosci, 269, 73–86.Google Scholar

Calabria, B., Degenhardt, L., Briegleb, C., et al. (2010). Systematic review of prospective studies investigating ‘remission’ from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav, 35, 741–749.Google Scholar

Cerdá, M., Mauro, C., Hamilton, A., et al. (2020). Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry, 77, 165–171.Google Scholar

Chen, C. Y., O’Brien, M. S., and Anthony, J. C. (2005). Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001. Drug Alcohol Depend, 79, 11–22.Google Scholar

Chen, C. Y., Storr, C. L., and Anthony, J. C. (2009). Early-onset drug use and risk for drug dependence problems. Addict Behav, 34, 319–322.Google Scholar

Chye, Y., Lorenzetti, V., Suo, C., et al. (2019). Alteration to hippocampal volume and shape confined to cannabis dependence: A multi‐site study. Addict Biol, 24, 822–834.Google Scholar

Coffey, C., and Patton, G. C. (2016). Cannabis use in adolescence and young adulthood: A review of findings from the Victorian Adolescent Health Cohort Study. Can J Psychiatry, 61, 318–327.Google Scholar

Cousijn, J., Wiers, R. W., Ridderinkhof, K. R., et al. (2014). Effect of baseline cannabis use and working‐memory network function on changes in cannabis use in heavy cannabis users: A prospective fMRI study. Hum Brain Mapp, 35, 2470–2482.Google Scholar

Curran, H. V., Freeman, T. P., Mokrysz, C., et al. (2016). Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci, 17, 293–306.Google Scholar

Curran, H. V., Hindocha, C., Morgan, C. J. A., et al. (2019). Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects? Psychol Med, 49, 1574–1580.Google Scholar

Cuttler, C., and Spradlin, A. (2017). Measuring cannabis consumption: Psychometric properties of the daily sessions, frequency, age of onset, and quantity of cannabis use inventory (DFAQ-CU). PLoS ONE, 12, e0178194.Google Scholar

D’Souza, D. C., Cortes-Briones, J., Creatura, G., et al. (2019). Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: A double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry, 6, 35–45.Google Scholar

D’Souza, D. C., Cortes-Briones, J. A., Ranganathan, M., et al. (2016). Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging, 1, 60–67.Google Scholar

Davis, M. L., Powers, M. B., Handelsman, P., et al. (2015). Behavioral therapies for treatment-seeking cannabis users: A meta-analysis of randomized controlled trials. Eval Health Prof, 38, 94–114.Google Scholar

Degenhardt, L., Charlson, F., Ferrari, A., et al. (2018). The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry, 5, 987–1012.Google Scholar

Dutra, L., Stathopoulou, G., Basden, S. L., et al. (2008). A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry, 165, 179–187.Google Scholar

EMCDDA. (2021). European Drug Report. Luxembourg: Publications Office of the European Union.Google Scholar

Ferland, J.-M. N., and Hurd, Y. L. (2020). Deconstructing the neurobiology of cannabis use disorder. Nat Neurosci, 23, 600–610.Google Scholar

Flórez-Salamanca, L., Secades-Villa, R., Hasin, D. S., et al. (2013). Probability and predictors of transition from abuse to dependence on alcohol, cannabis, and cocaine: Results from the national epidemiologic survey on alcohol and related conditions. Am J Drug Alcohol Abuse, 39, 168–179.Google Scholar

Freeman, A. M., Petrilli, K., Lees, R., et al. (2019). How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev, 107, 696–712.Google Scholar

Freeman, T. P., Craft, S., Wilson, J., et al. (2021). Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: Systematic review and meta‐analysis. Addiction, 116, 1000–1010.Google Scholar

Freeman, T. P., Hindocha, C., Baio, G., et al. (2020). Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry, 7(10), pp. 865–874.Google Scholar

Freeman, T. P., and Lorenzetti, V. (2020). ‘Standard THC units’: A proposal to standardize dose across all cannabis products and methods of administration. Addiction, 115, 1207–1216.Google Scholar

Freeman, T. P., van der Pol, P., Kuijpers, W., et al. (2018). Changes in cannabis potency and first-time admissions to drug treatment: A 16-year study in the Netherlands. Psychol Med, 48, 2346–2352.Google Scholar

Freeman, T. P., and Winstock, A. R. (2015). Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med, 45, 3181–3189.Google Scholar

Galve-Roperh, I., Palazuelos, J., Aguado, T., et al. (2009). The endocannabinoid system and the regulation of neural development: Potential implications in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci, 259, 371–382.Google Scholar

Gates, P. J., Sabioni, P., Copeland, J., et al. (2016). Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev, 2016, CD005336.Google Scholar

Giedd, J. N., Blumenthal, J., Jeffries, N. O., et al. (1999). Brain development during childhood and adolescence: A longitudinal MRI study. Nat Neurosci, 2, 861–863.Google Scholar

Gray, K. M., Sonne, S. C., McClure, E. A., et al. (2017). A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend, 177, 249–257.Google Scholar

Hall, W., and Lynskey, M. (2020). Assessing the public health impacts of legalizing recreational cannabis use: The US experience. World Psychiatry, 19, 179–186.Google Scholar

Han, B., Compton, W. M., Blanco, C., et al. (2019). Time since first cannabis use and 12‐month prevalence of cannabis use disorder among youth and emerging adults in the United States. Addiction, 114, 698–707.Google Scholar

Hasin, D. S., Kerridge, B. T., Saha, T. D., et al. (2016). Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions–III. Am J Psychiatry, 173, 588–599.Google Scholar

Heilig, M., MacKillop, J., Martinez, D., et al. (2021). Addiction as a brain disease revised: Why it still matters, and the need for consilience. Neuropsychopharmacology, 46, 1715–1723.Google Scholar

Hill, K. P., Palastro, M. D., Gruber, S. A., et al. (2017). Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study. Am J Addict, 26, 795–801.Google Scholar

Hindocha, C., Shaban, N. D. C., Freeman, T. P., et al. (2015). Associations between cigarette smoking and cannabis dependence: A longitudinal study of young cannabis users in the United Kingdom. Drug Alcohol Depend, 148, 165–171.Google Scholar

Hines, L. A., Freeman, T. P., Gage, S. H., et al. (2020). Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiatry, 77, 1044–1051.Google Scholar

Hines, L. A., Morley, K. I., Strang, J., et al. (2016). Onset of opportunity to use cannabis and progression from opportunity to dependence: Are influences consistent across transitions? Drug Alcohol Depend, 160, 57–64.Google Scholar

Huestis, M. A., Gorelick, D. A., Heishman, S. J., et al. (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry, 58, 322–328.Google Scholar

Johnson, E. C., Demontis, D., Thorgeirsson, T. E., et al. (2020). A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry, 7, 1032–1045.Google Scholar

Lawn W, Mokrysz C, Lees, R et al. (2022). The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls. J Psychopharmacol. 36, 1350–1361.Google Scholar

Lees, R., Hines, L. A., D’Souza, D. C., et al. (2021). Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: A narrative review. Psychol Med, 51, 353–364.Google Scholar

Leung, J., Chan, G. C. K., Hides, L., et al. (2020). What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addict Behav, 109, 106479.Google Scholar

Leung, J., Chiu, C. Y. V., Stjepanović, D., et al. (2018). Has the legalisation of medical and recreational cannabis use in the USA affected the prevalence of cannabis use and cannabis use disorders? Curr Addict Rep, 5, 403–417.Google Scholar

Levin, F. R., Mariani, J. J., Brooks, D. J., et al. (2011). Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend, 116, 142–150.Google Scholar

Lintzeris, N., Bhardwaj, A., Mills, L., et al. (2019). Nabiximols for the treatment of cannabis dependence: A randomized clinical trial. JAMA Intern Med, 179, 1242–1253.Google Scholar

Loflin, M. J. E., Kiluk, B. D., Huestis, M. A., et al. (2020). The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug Alcohol Depend, 212, 107993.Google Scholar

Lopez‐Quintero, C., Hasin, D. S., de los Cobos, J. P., et al. (2011a). Probability and predictors of remission from life‐time nicotine, alcohol, cannabis or cocaine dependence: Results from the national epidemiologic survey on alcohol and related conditions. Addiction, 106, 657–669.Google Scholar

Lopez-Quintero, C., Pérez de los Cobos, J., Hasin, D. S., et al. (2011b). Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend, 115, 120–130.Google Scholar

Lorenzetti, V., Chye, Y., Suo, C., et al. (2020). Neuroanatomical alterations in people with high and low cannabis dependence. Aust NZ J Psychiatry, 54, 68–75.Google Scholar

Lubman, D. I., Yücel, M., and Hall, W. D. (2007). Substance use and the adolescent brain: A toxic combination? J Psychopharmacol, 21, 792–794.Google Scholar

Marel, C., Sunderland, M., Mills, K. L., et al. (2019). Conditional probabilities of substance use disorders and associated risk factors: Progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives and opioids. Drug Alcohol Depend, 194, 136–142.Google Scholar

Mason, B. J., Crean, R., Goodell, V., et al. (2012). A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology, 37, 1689–1698.Google Scholar

Millar, S. R., Mongan, D., Smyth, B. P., et al. (2021). Relationships between age at first substance use and persistence of cannabis use and cannabis use disorder. BMC Public Health, 21, 1–11.Google Scholar

Miranda, R. Jr, Treloar, H., Blanchard, A., et al. (2017). Topiramate and motivational enhancement therapy for cannabis use among youth: A randomized placebo‐controlled pilot study. Addict Biol, 22, 779–790.Google Scholar

Mokrysz, C., Freeman, T. P., Korkki, S., et al. (2016). Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Transl Psychiatry, 6, e961–e961.Google Scholar

Nielsen, S., Gowing, L., Sabioni, P., et al. (2019). Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev, 1, CD008940.Google Scholar

Papinczak, Z. E., Connor, J. P., Feeney, G. F. X., et al. (2019). Testing the biosocial cognitive model of substance use in cannabis users referred to treatment. Drug Alcohol Depend, 194, 216–224.Google Scholar

Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin. Br J Pharmacol, 153, 199–215.Google Scholar

van der Pol, P., Liebregts, N., de Graaf, R., et al. (2013a). Mental health differences between frequent cannabis users with and without dependence and the general population. Addiction, 108, 1459–1469.Google Scholar

van der Pol, P., Liebregts, N., de Graaf, R., et al. (2013b). Predicting the transition from frequent cannabis use to cannabis dependence: A three-year prospective study. Drug Alcohol Depend, 133, 352–359.Google Scholar

Ramaekers, J. G., Mason, N. L., Kloft, L., et al. (2021). The why behind the high: Determinants of neurocognition during acute cannabis exposure. Nat Rev Neurosci, 22, 439–454.Google Scholar

Schettino, J., and Hoch, E. (2015). Treatment of Cannabis-related Disorders in Europe. Luxembourg: Publications Office of the European Union.Google Scholar

Schlag, A. K., Hindocha, C., Zafar, R., et al. (2021). Cannabis based medicines and cannabis dependence: A critical review of issues and evidence. J Psychopharmacol, 35, 773–785.Google Scholar

Skumlien, M., Freeman, T. P, Hall, R. et al. (2022a). The effects of acute cannabis with and without cannabidiol on neural reward anticipation in adults and adolescents, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging (2022), doi.org/10.1016/j.bpsc.2022.10.004.Google Scholar

Skumlien, M., Mokrysz, C., Freeman, T. P. et al. (2022b). Neural responses to reward anticipation and feedback in adult and adolescent cannabis users and controls. Neuropsychopharmacology. 47, 1976–1983.Google Scholar

von Sydow, K., Lieb, R., Pfister, H., et al. (2001). The natural course of cannabis use, abuse and dependence over four years: A longitudinal community study of adolescents and young adults. Drug Alcohol Depend, 64, 347–361.Google Scholar

von Sydow, K., Lieb, R., Pfister, H., et al. (2002). What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend, 68, 49–64.Google Scholar

Teesson, M., Slade, T., Swift, W., et al. (2012). Prevalence, correlates and comorbidity of DSM-IV cannabis use and cannabis use disorders in Australia. Aust NZ J Psychiatry, 46, 1182–1192.Google Scholar

UNODC. (2017). World Drug Report. Geneva: United Nations.Google Scholar

UNODC. (2020). World Drug Report. Geneva: United Nations.Google Scholar

Urban, N. B. L., Slifstein, M., Thompson, J. L., et al. (2012). Dopamine release in chronic cannabis users: A [11c] raclopride positron emission tomography study. Biol Psychiatry, 71, 677–683.Google Scholar

Verweij, K. J. H., Abdellaoui, A., Nivard, M. G., et al. (2017). Genetic association between schizophrenia and cannabis use. Drug Alcohol Depend, 171, 117–121.Google Scholar

Vingerhoets, W. A. M., Koenders, L., van den Brink, W., et al. (2016). Cue-induced striatal activity in frequent cannabis users independently predicts cannabis problem severity three years later. J Psychopharmacol, 30, 152–158.Google Scholar

Volkow, N. (2021). Establishing 5 mg of THC as the Standard Unit for Research. Available at: www.drugabuse.gov/about-nida/noras-blog/2021/05/establishing-5mg-thc-standard-unit-research. Last accessed 31 October 2022.Google Scholar

Volkow, N. D., Han, B., Einstein, E. B., et al. (2021). Prevalence of substance use disorders by time since first substance use among young people in the US. JAMA Pediatr, 175, 640–643.Google Scholar

WHO. (2018). International Classification of Diseases for Mortality and Morbidity Statistics (11th Revision). Geneva: World Health Organization.Google Scholar

Wittchen, H. U., Jacobi, F., Rehm, J., et al. (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol, 21, 655–679.Google Scholar

Adermark, L. (2011). Modulation of endocannabinoid-mediated long-lasting disinhibition of striatal output by cholinergic interneurons. Neuropharmacology, 61, 1314–1320.Google Scholar

Agrawal, A., and Lynskey, M. T. (2009). Tobacco and cannabis co-occurrence: Does route of administration matter? Drug Alcohol Depend, 99, 240–247.Google Scholar

Agrawal, A., Silberg, J. L., Lynskey, M. T., et al. (2010). Mechanisms underlying the lifetime co-occurrence of tobacco and cannabis use in adolescent and young adult twins. Drug Alcohol Depend, 108, 49–55.Google Scholar

Akbar, S. A., Tomko, R. L., Salazar, C. A., et al. (2019). Tobacco and cannabis co-use and interrelatedness among adults. Addict Behav, 90, 354–361.Google Scholar

Ambrose, B. K., Rostron, B. L., Johnson, S. E., et al. (2014). Perceptions of the relative harm of cigarettes and e-cigarettes among U.S. youth. Am J Prev Med, 47, S53–S60.Google Scholar

Belanger, R. E., Marclay, F., Berchtold, A., et al. (2013). To what extent does adding tobacco to cannabis expose young users to nicotine? Nicotine Tob Res, 15, 1832–1838.Google Scholar

Berg, C. J., Payne, J., Henriksen, L., et al. (2018). Reasons for marijuana and tobacco co-use among young adults: A mixed methods scale development study. Subst Use Misuse, 53, 357–369.Google Scholar